Abstract: A microfluidic structure in which a plurality of chambers arranged at different positions are connected in parallel and into which a fixed amount of fluid may be efficiently distributed without using a separate driving source, and a microfluidic device having the same. The microfluidic device includes a platform having a center of rotation and including at least one microfluidic structure. The microfluidic structure includes a sample supply chamber configured to accommodate a sample, a plurality of first chambers arranged in a circumferential direction of the platform at different distances from the center of rotation of the platform, and a plurality of siphon channels, each of the siphon channels being connected to a corresponding one of the first chambers.

Abstract: A microfluidic structure in which a plurality of chambers arranged at different positions are connected in parallel and into which a fixed amount of fluid may be efficiently distributed without using a separate driving source, and a microfluidic device having the same. The microfluidic device includes a platform having a center of rotation and including at least one microfluidic structure. The microfluidic structure includes a sample supply chamber configured to accommodate a sample, a plurality of first chambers arranged in a circumferential direction of the platform at different distances from the center of rotation of the platform, and a plurality of siphon channels, each of the siphon channels being connected to a corresponding one of the first chambers.

Abstract: A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like. The NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma. In order to obtain antibodies with specific binding properties for targeted amino acid sequences within human proBNP, recombinant human proBNP (or rhproBNP) was expressed and purified for use as an immunogen. Polyclonal antibodies (PAb) to specific amino acid sequences were subsequently purified from goat serum by sequential affinity purification. Monoclonal antibodies were raised against specific polypeptides. Recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified in order to obtain material for use in calibration of a quantitative method for measurement of human NT-proBNP.

Abstract: The present invention provides an apparatus for retaining solid state reagents and/or for processing sample for a diagnostic test, where the apparatus avoids liquid “hang-up” that would otherwise result in loss of sample or fluid volume during sample transfer. The invention further provides diagnostic methods that employ the apparatus, so as to provide sensitive and accurate analyte detection.

Abstract: A test apparatus is provided for rapidly detecting abnormal loading of a microfluidic device, and unloading the abnormally-loaded microfluidic device, thereby preventing contamination of the test apparatus by a sample and degradation in reliability of test results. A test system including the test apparatus and a control method for the test apparatus are also provided. The test apparatus includes an optical sensor to photograph an image at a position corresponding to the microfluidic device, and a controller to detect a pattern formed on a surface of the microfluidic device based on the photographed image to determine whether characteristics of the detected pattern are identical to characteristics of a pre-stored pattern, and to determine whether the microfluidic device has not been normally loaded, when the characteristics of the detected pattern are different from the characteristics of the pre-stored pattern.

Abstract: The present invention provides an apparatus for retaining solid state reagents and/or for processing sample for a diagnostic test, where the apparatus avoids liquid “hang-up” that would otherwise result in loss of sample or fluid volume during sample transfer. The invention further provides diagnostic methods that employ the apparatus, so as to provide sensitive and accurate analyte detection.

Abstract: The invention provides compositions, systems and methods for detecting multiple analytes from a sample.

Abstract: A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like.

Abstract: A diagnostic assay system including a test device and a scanning device are described. In one implementation, the scanning device includes a source of electromagnetic radiation, an optics assembly, a detector, and a microprocessor disposed within a chassis. The test device and scanning device may be configured to be movable relative to each other during operation of the scanning device.

Abstract: The invention provides compositions, systems and methods for detecting multiple analytes from a sample.

Abstract: The present invention provides methods and devices for detecting the presence of two or more threshold levels of an analyte, including markers of myocardial damage such as cardiac troponins, in a sample. In various embodiments, the invention provides convenient point-of-care tests for determining the condition of a patient, so as to guide cost effective health care.

Abstract: The present invention provides an apparatus for retaining solid state reagents and/or for processing sample for a diagnostic test, where the apparatus avoids liquid “hang-up” that would otherwise result in loss of sample or fluid volume during sample transfer. The invention further provides diagnostic methods that employ the apparatus, so as to provide sensitive and accurate analyte detection.

Abstract: A diagnostic assay system including a test device and a scanning device are described. In one implementation, the scanning device includes a source of electromagnetic radiation, an optics assembly, a detector, and a microprocessor disposed within a chassis. The test device and scanning device may be configured to be movable relative to each other during operation of the scanning device.

Abstract: The invention provides an assay for the quantification of circulating glycophorin in biological fluid samples. The circulating glycophorin measured by this assay is a truncated glycophorin diagnostic for congestive heart failure (CHF).

Abstract: The invention describes methods for predicting outcome for patients suffering from traumatic brain injury (TBI) by evaluating levels of markers commonly associated with cellular damage in bodily fluids. Utilization of such methods improves diagnosis and treatment of patients suffering from traumatic brain injury, thus potentially minimizing and/or eliminating long-term adverse effects in these patients.

Abstract: A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like. The NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma. In order to obtain antibodies with specific binding properties for targeted amino acid sequences within human proBNP, recombinant human proBNP (or rhproBNP) was expressed and purified for use as an immunogen. Polyclonal antibodies (PAb) to specific amino acid sequences were subsequently purified from goat serum by sequential affinity purification. Monoclonal antibodies were raised against specific polypeptides. Recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified in order to obtain material for use in calibration of a quantitative method for measurement of human NT-proBNP.

Abstract: The present invention is directed to methods and apparatus for detection of one or more analytes. Analytes include agents or components of infectious agents such as pathogenic virus, as well as enzymes, proteins and biomarkers.

Abstract: The invention provides an assay for the quantification of circulating glycophorin in biological fluid samples. The circulating glycophorin measured by this assay is a truncated glycophorin diagnostic for congestive heart failure (CHF).

Abstract: A method for determining whether a subject has had a stroke and, if so, the type of stroke which includes analyzing the subject's body fluid for at least four selected markers of stroke, namely, myelin basic protein, S100 protein, neuronal specific enolase and a brain endothelial membrane protein such as thrombomodulin or a similar molecule. The data obtained from the analyses provide information as to the type of stroke, the onset of occurrence and the extent of brain damage and allow a physician to determine quickly the type of treatment required by the subject.

Abstract: The present invention is directed to methods and apparatus for detection of one or more analytes. Analytes include agents or components of infectious agents such as pathogenic virus, as well as enzymes, proteins and biomarkers.